Cargando…

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis

INTRODUCTION: We sought to assess adherence to and persistence with ocrelizumab (OCR) compared with other disease-modifying treatments (DMTs), by route of administration (RoA), for multiple sclerosis (MS) after 24 months in the United States. METHODS: This retrospective claims analysis of MS patient...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pardo, Gabriel, Pineda, Elmor D., Ng, Carmen D., Bawa, Komal K., Sheinson, Daniel, Bonine, Nicole G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857349/ https://www.ncbi.nlm.nih.gov/pubmed/35020156 http://dx.doi.org/10.1007/s40120-021-00319-3

Ejemplares similares

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab
por: Geiger, Caroline K., et al.
Publicado: (2023)

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
por: Halpern, Rachel, et al.
Publicado: (2011)

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
por: Zanga, Gisela, et al.
Publicado: (2021)

Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis
por: Fox, David, et al.
Publicado: (2022)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

Healthcare Resource Use and Burden Associated with Influenza Transmission Among Household Members with a Primary Infection: Commercial Claims Data Analysis
por: Wallick, Christopher, et al.
Publicado: (2021)

PB2081: TREATMENT PERSISTENCE AND ADHERENCE TO IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: A GERMAN CLAIMS DATA ANALYSIS
por: Buske, C., et al.
Publicado: (2022)

Medication adherence/persistence among patients with active multiple sclerosis in Finland
por: Lahdenperä, Sanni, et al.
Publicado: (2020)

Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database
por: Fan, Tao, et al.
Publicado: (2013)

Persistence at 24 months with denosumab among postmenopausal women with osteoporosis: results of a prospective cohort study
por: Silverman, Stuart L., et al.
Publicado: (2018)

Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database
por: Shirai, Chikako, et al.
Publicado: (2021)

Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis
por: Li, Gang, et al.
Publicado: (2021)

Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
por: Nishimura, Rimei, et al.
Publicado: (2019)

COVID-19 and adherence to biologic therapies for psoriasis: An analysis of nationwide pharmacy claims data
por: He, Meiqi, et al.
Publicado: (2022)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data
por: Jang, Yunjeong, et al.
Publicado: (2021)

Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men
por: van den Elshout, Mark AM, et al.
Publicado: (2023)

Adherence to Glaucoma Medications Over 12 Months in Two US Community Pharmacy Chains
por: Feehan, Michael, et al.
Publicado: (2016)

FATHER–CHILD INTERACTIONS AT 3 MONTHS AND 24 MONTHS: CONTRIBUTIONS TO CHILDREN'S COGNITIVE DEVELOPMENT AT 24 MONTHS
por: Sethna, Vaheshta, et al.
Publicado: (2017)

The impact of GI events on persistence and adherence to osteoporosis treatment: 3-, 6-, and 12-month findings in the MUSIC-OS study
por: Modi, A., et al.
Publicado: (2017)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

The Return of the Repressed: The Persistent and Problematic Claims of Long-Forgotten Trauma
por: Otgaar, Henry, et al.
Publicado: (2019)

Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)
por: Keyloun, Katelyn R., et al.
Publicado: (2017)

Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases
por: Moran, Kellyn, et al.
Publicado: (2019)

Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
por: Alosaimi, Fahad D, et al.
Publicado: (2017)

Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women
por: Freemantle, N., et al.
Publicado: (2011)

HIV status, breastfeeding modality at 5 months and postpartum maternal weight changes over 24 months in rural South Africa
por: Chetty, Terusha, et al.
Publicado: (2014)

Real-world persistence and benefit–risk profile of fingolimod over 36 months in Germany
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Trends in Early Growth Indices in the First 24 Months of Life in Uruguay over the Past Decade
por: Bove, Isabel, et al.
Publicado: (2014)

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims
por: Stephenson, J J, et al.
Publicado: (2012)

The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations
por: Pardo, Gabriel, et al.
Publicado: (2017)

Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data
por: Kuwabara, Hiroyo, et al.
Publicado: (2015)

Real-World Analysis Affirms the High Persistence and Adherence Observed with Diroximel Fumarate in Patients with Multiple Sclerosis
por: Lager, Brittney, et al.
Publicado: (2022)

Comment on: “Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”
por: Woolcott, John, et al.
Publicado: (2020)

Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis
por: Gor, Deval, et al.
Publicado: (2020)

The Impact of Funding Inpatient Treatments for COVID-19 on Health Equity in the United States: A Distributional Cost-Effectiveness Analysis
por: Kowal, Stacey, et al.
Publicado: (2023)

Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications
por: Pineda, Elmor D., et al.
Publicado: (2020)

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
por: Morillo Verdugo, Ramón, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vb75qb9dnb2kaa2q33uua041ia